Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules
Andrey D. Bondarev, Misty M. Attwood, Jörgen Jönsson, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 6, pp. 537-552
Closed Access | Times Cited: 42
Vorinostat (SAHA) and Breast Cancer: An Overview
Anna Wawruszak, Lidia Borkiewicz, Estera Okoń, et al.
Cancers (2021) Vol. 13, Iss. 18, pp. 4700-4700
Open Access | Times Cited: 73
Identification of the extracellular membrane protein ENPP3 as a major cGAMP hydrolase and innate immune checkpoint
Rachel Mardjuki, Songnan Wang, Jacqueline A. Carozza, et al.
Cell Reports (2024) Vol. 43, Iss. 5, pp. 114209-114209
Open Access | Times Cited: 10
Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling
Jingjing Zhang, X. Ye, Xuesong Liu, et al.
World Journal of Cardiology (2025) Vol. 17, Iss. 1
Closed Access | Times Cited: 1
Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions
Nuno Jorge Lamas, Arnaud Martel, Sacha Nahon‐Estève, et al.
Cancers (2021) Vol. 14, Iss. 1, pp. 96-96
Open Access | Times Cited: 42
Phosphodiesterase inhibitors in psychiatric disorders
Mohammad Amin Sadeghi, Ehsan Nassireslami, Mojtaba Yousefi Zoshk, et al.
Psychopharmacology (2023) Vol. 240, Iss. 6, pp. 1201-1219
Closed Access | Times Cited: 20
Phosphodiesterase in heart and vessels: from physiology to diseases
Qin Fu, Ying Wang, Chen Yan, et al.
Physiological Reviews (2023) Vol. 104, Iss. 2, pp. 765-834
Open Access | Times Cited: 18
Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases
Yu Xiang, Swapna Naik, Liyun Zhao, et al.
Medicinal Research Reviews (2024) Vol. 44, Iss. 4, pp. 1404-1445
Closed Access | Times Cited: 7
Beyond PDE4 inhibition: A comprehensive review on downstream cAMP signaling in the central nervous system
Zoë Donders, Iga Joanna Skorupska, Emily Willems, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117009-117009
Open Access | Times Cited: 7
Identification of extracellular membrane protein ENPP3 as a major cGAMP hydrolase, cementing cGAMP's role as an immunotransmitter
Rachel Mardjuki, Songnan Wang, Jacqueline A. Carozza, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases
Qi Li, Qinghong Liao, Shulei Qi, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116386-116386
Closed Access | Times Cited: 6
The Impact of Body Mass Index and Benign Prostatic Hyperplasia on Bone Health of Middle‐Aged and Older Men
Tzyy‐Ling Chuang, Pao‐Liang Chen, Malcolm Koo, et al.
Obesity Science & Practice (2025) Vol. 11, Iss. 1
Open Access
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape
Preetika Govil, Joshua T. Kantrowitz
CNS Drugs (2025)
Closed Access
The Impact of the Exposome on Alzheimer’s Disease: The Influence of Nutrition
Martina Monaco, Carola Torazza, Ernesto Fedele, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3015-3015
Open Access
Neuroprotective Effects of Cilomilast and Chlorogenic Acid Against Scopolamine-Induced Memory Deficits via Modulation of the cAMP/PKA–CREB–BDNF Pathway
Esraa M. Mosalam, Soha Mohamed Atya, Noha M. Mesbah, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3108-3108
Open Access
New pharmacological approaches in the treatment of schizophrenia
Józef Muszyński, Agnieszka Bienert, Rasha Wafaie Mahmoud Elsorady, et al.
Pharmacological Reports (2025)
Closed Access
Targeting phosphodiesterase 4 as a potential therapy for Parkinson’s disease: a review
Pooja Devi Nongthombam, Reena Haobam
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 4
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
Michela Salvadè, Mónica Di Luca, Fabrizio Gardoni
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117862-117862
Closed Access
The alphavirus nonstructural protein 2 NTPase induces a host translational shut-off through phosphorylation of eEF2 via cAMP-PKA-eEF2K signaling
Emmely E. Treffers, Ali Taş, Florine E. M. Scholte, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 2, pp. e1011179-e1011179
Open Access | Times Cited: 9
The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs
Eugenia D. Namiot, Diana Smirnovová, Aleksandr V. Sokolov, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
ALDOA coordinates PDE3A through the β-catenin/ID3 axis to stimulate cancer metastasis and M2 polarization in lung cancer with EGFR mutations
Chia-Ying Yeh, Huei Yu Cai, Han-His Kuo, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 696, pp. 149489-149489
Closed Access | Times Cited: 2
[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review
Miguel Mansilla‐Polo, E Gimeno, D. Morgado‐Carrasco
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 3, pp. T265-T279
Open Access | Times Cited: 2
Beyond traditional pharmacology: evaluating phosphodiesterase inhibitors in autism spectrum disorder
Fernando E. Padovan‐Neto, Ana Júlia de Oliveira Cerveira, Aline da Silva, et al.
Neuropsychopharmacology (2024) Vol. 49, Iss. 9, pp. 1359-1360
Closed Access | Times Cited: 2
Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets
Justin R. Yates
Substance Abuse and Rehabilitation (2024) Vol. Volume 15, pp. 125-161
Open Access | Times Cited: 2
Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales
Andrey D. Bondarev, Jörgen Jönsson, Vladimir N. Chubarev, et al.
Pharmacological Research (2024) Vol. 209, pp. 107431-107431
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top